About us

• Mission and strategy
• Organisation
• Our partners
  • Research partners
  • Allies
  • Donors and sponsors
• Financials
• Registration and documents
• Downloads
• Contact

1. TBVI »
2. About us »
3. Our partners »
4. Donors and sponsors

Without support of donors and sponsors TBVI would never be able to continue the research and development of the urgently needed new tuberculosis vaccines. There are many reasons to invest in the fight against tuberculosis. We are grateful for the support of:

Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty.

EU 7th Framework Programme
The Seventh Framework Programme for Research and Technological Development (2007-2013) is the European Union’s main instrument for funding research in Europe. FP7 is also designed to respond to Europe's employment needs, competitiveness and quality of life.

FIT Biotech Ltd
FIT Biotech is an innovative medical biotechnology company from Finland. It has developed a promising DNA vaccination technology that will be applied to develop concrete new, more efficient tuberculosis vaccines.

Institut Mérieux
Institut Mérieux is committing its experience in industrial biology to serve medicine and public health across the globe. To fight against infectious diseases and cancers, it imagines and develops new approaches in the fields of diagnostics, immunotherapy, food safety and nutrition.

GlaxoSmithKline (GSK) Biologicals
GlaxoSmithKline Biologicals (GSK Biologicals), GlaxoSmithKline’s vaccines business, is one of the world’s leading vaccine companies and a leader in innovation. The company is active in vaccine research, development and production with over 30 vaccines approved for marketing and 20 more in development - both in the prophylactic and therapeutic fields. Through its accomplished and dedicated workforce, GSK Biologicals applies its expertise to the discovery of innovative vaccines that contribute to the health and well-being of people of all generations around the world.

Calouste Gulbenkian Foundation
The Calouste Gulbenkian Foundation is a charitable foundation established in Portugal in 1956 with cultural, educational, social and scientific interests. The Foundation’s Headquarters are in Lisbon with offices in London (the UK Branch) and Paris. Its founder, Calouste Gulbenkian, was an Armenian born in Turkey who worked in Britain and became a British citizen, lived in France and settled in Portugal. He was multicultural and multilingual and spent his career bringing people from different cultures and nationalities together.

EDCTP
The European and Developing Countries Clinical Trial Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, malaria and tuberculosis, with a focus on phase II and III clinical trials in sub-Saharan Africa. EDCTP supports multicentre projects which combine clinical trials, capacity building and networking. The aim of integrating these three activities is to ensure that the developed capacity is optimally utilised to successfully conduct the clinical trials in a sustainable way.

Biofabri
Biofabri is a biopharmaceutical company that was created in 2008 with a vision: to research, develop and manufacture human vaccines.  With over 70 years of experience Biofabri focuses on two strategic business lines: the biological production of vaccines for human use and the pharmaceutical division, being specialised in contract manufacturing and distribution of pharmaceutical products.